Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | MicrobiomeTrials← Back to trialsNCT07638787
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2027-09-30
Enrollment target: 40 participants Locations- Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in
DLBCL - Diffuse Large B Cell Lymphoma
This study will ultimately aim at providing the scientific community with patient-reported health status data that will …
Bologna, ItalyCompleted Feb 15, 2024
Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Waldenström Macroglobulinemia (WM)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and c…
Multiple Locations
Est. completion Jun 30, 2029